Spineart secured a €30MM (~US $33MM) investment. Proceeds will support sales, geographical expansion in markets such as the U.S. and Europe and product development.
Funds were provided by Gimv, an investment company, and Health and Care Fund.
Spineart has secured numerous FDA 510(k) clearances in the U.S. since 2008, and was recently granted CE Mark Approval for its JULIET®Ti lumbar interbody systems featuring TI-LIFE, a micro-porous scaffold designed to mimic trabecular bone.
Sources: Spineart; FDA.gov; ORTHOWORLD Inc.
Spineart secured a €30MM (~US $33MM) investment. Proceeds will support sales, geographical expansion in markets such as the U.S. and Europe and product development.
Funds were provided by Gimv, an investment company, and Health and Care Fund.
Spineart has secured numerous FDA 510(k) clearances in the U.S. since 2008, and was recently...
Spineart secured a €30MM (~US $33MM) investment. Proceeds will support sales, geographical expansion in markets such as the U.S. and Europe and product development.
Funds were provided by Gimv, an investment company, and Health and Care Fund.
Spineart has secured numerous FDA 510(k) clearances in the U.S. since 2008, and was recently granted CE Mark Approval for its JULIET®Ti lumbar interbody systems featuring TI-LIFE, a micro-porous scaffold designed to mimic trabecular bone.
Sources: Spineart; FDA.gov; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.